Lalit Saini1, Joseph Brandwein2,3. 1. Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada. 2. Division of Hematology, Department of Medicine, University of Alberta, Edmonton, AB, Canada. jbrandwe@ualberta.ca. 3. , 11350 - 83 Avenue Suite 4-112 Clinical Sciences Building, Edmonton, AB, T6G 2G3, Canada. jbrandwe@ualberta.ca.
Abstract
PURPOSE OF REVIEW: To review recent studies that address important questions regarding the treatment of Philadelphia chromosome-positive ALL. RECENT FINDINGS: Less intensive non-myelosuppressive induction approaches can produce comparable anti-leukemic responses with less toxicity. Second-generation tyrosine kinase inhibitors (TKIs) are not clearly associated with superior outcomes compared to imatinib. Ponatinib is associated with lower early relapse rates, but has additional vascular risks. Patients achieving complete molecular response (CMR) appear to have comparable survivals with chemotherapy + TKI alone as compared with allogeneic stem cell transplant (alloSCT). In contrast, those not achieving CMR have superior outcomes with alloSCT. There is no clear evidence of benefit for post-transplant TKI therapy. Patients resistant to chemotherapy + TKIs may respond to blinatumomab or inotuzumab; these agents may also convert some patients to CMR. Future studies should further explore the potential of ponatinib and antibody-based therapies to more precisely define optimal molecular responses.
PURPOSE OF REVIEW: To review recent studies that address important questions regarding the treatment of Philadelphia chromosome-positive ALL. RECENT FINDINGS: Less intensive non-myelosuppressive induction approaches can produce comparable anti-leukemic responses with less toxicity. Second-generation tyrosine kinase inhibitors (TKIs) are not clearly associated with superior outcomes compared to imatinib. Ponatinib is associated with lower early relapse rates, but has additional vascular risks. Patients achieving complete molecular response (CMR) appear to have comparable survivals with chemotherapy + TKI alone as compared with allogeneic stem cell transplant (alloSCT). In contrast, those not achieving CMR have superior outcomes with alloSCT. There is no clear evidence of benefit for post-transplant TKI therapy. Patients resistant to chemotherapy + TKIs may respond to blinatumomab or inotuzumab; these agents may also convert some patients to CMR. Future studies should further explore the potential of ponatinib and antibody-based therapies to more precisely define optimal molecular responses.
Authors: S Couban; L Savoie; Y Abou Mourad; B Leber; M Minden; R Turner; V Palada; N Shehata; A Christofides; S Lachance Journal: Curr Oncol Date: 2014-04 Impact factor: 3.677
Authors: Max S Topp; Peter Kufer; Nicola Gökbuget; Mariele Goebeler; Matthias Klinger; Svenja Neumann; Heinz-A Horst; Thorsten Raff; Andreas Viardot; Mathias Schmid; Matthias Stelljes; Markus Schaich; Evelyn Degenhard; Rudolf Köhne-Volland; Monika Brüggemann; Oliver Ottmann; Heike Pfeifer; Thomas Burmeister; Dirk Nagorsen; Margit Schmidt; Ralf Lutterbuese; Carsten Reinhardt; Patrick A Baeuerle; Michael Kneba; Hermann Einsele; Gert Riethmüller; Dieter Hoelzer; Gerhard Zugmaier; Ralf C Bargou Journal: J Clin Oncol Date: 2011-05-16 Impact factor: 44.544
Authors: K R Schultz; A Carroll; N A Heerema; W P Bowman; A Aledo; W B Slayton; H Sather; M Devidas; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta Journal: Leukemia Date: 2014-01-20 Impact factor: 11.528
Authors: Giovanni Martinelli; Nicolas Boissel; Patrice Chevallier; Oliver Ottmann; Nicola Gökbuget; Max S Topp; Adele K Fielding; Alessandro Rambaldi; Ellen K Ritchie; Cristina Papayannidis; Lulu Ren Sterling; Jonathan Benjamin; Anthony Stein Journal: J Clin Oncol Date: 2017-03-29 Impact factor: 44.544
Authors: Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone Journal: Blood Date: 2013-11-25 Impact factor: 22.113
Authors: M N Lyu; E L Jiang; Y He; D L Yang; Q L Ma; A M Pang; W H Zhai; J L Wei; Y Huang; G X Zhang; R L Zhang; S Z Feng; M Z Han Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2020-05-14